Phage4BacID project

Project title Phage4BacID
Project code 033603
Main objective Bacteriophages in the Diagnosis and Prevention of Multiresistant Infections in Portugal and the World
Region of intervention Lisbon
Beneficiary entity TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA S.A.; INESC Microsistemas e Nanotecnologias – Instituto de Engenharia de Sistemas e Computadores para os Microsistemas e as Nanotecnologias; and Instituto Superior Técnico
Approval date May 2018
Start date May 2018
End date April 2020
Total eligible cost 1.482.004,18€
Regional public financial support 592.801,67€
Objectives, activities and expected results The current project proposes the development of a biochip for the rapid diagnostics of potentially problematic high risk bacterial clones, using biologic products of patients admitted in the emergency room. In 8 hours or less, it will be possible to screen the presence of infection or colonization caused by these prevalent clones, leading to the isolation of the patient and preventing the dissemination of the pathogenic agent. This system will be based in the classic methodology of phage typing that will be here allied to the innovative technology of biochips, allowing the prevention of the dissemination of problematic hospital-acquired bacteria.

Inflam.PT project

Project title | Inflam.PT
Project code | 011261
Main objective | Development of an innovative therapeutic agent for autoimmune diseases
Region of intervention | Lisbon
Approval date | 13 May 2016
Start date | January 2016
End date | December 2017
Total eligible cost | 431.539,09€
Regional public financial support | 172.637,24€
Objectives, activities and expected results | Inflam.PT project consists in the development of a specific antibody for the treatment of rheumatoid arthritis and systemic lupus erythematosus. Both diseases have a major incidence in the Asian region, particularly in China.
Inflam.PT project targets a proinflammatory cytokine that plays a role in T cell activation, acute phase protein production in response to inflammation, induction of immunoglobulin production, and stimulation of osteoclast differentiation and activation.

NeuroGoInter project

Project title NeuroGoInter
Project code 002452
Main objective Internationalization of the area of R&D of neurology
Region of intervention Lisbon
Approval date 14 September 2015
Start date December 2015
End date November 2017
Total eligible cost 99.275,00€
Regional public financial support 44.673,75€
Objectives, activities and expected results NeuroGoInter project intends to initiate the internationalization process of TA-111 and TZ-113 products in the markets of Alzheimer’s disease and Parkinson’s disease, respectively. Currently, TechnoPhage faces two challenges, chained in time:
– a first phase, under the NeuroGoInter project, broadening its international network and promoting advances in the R&D of TA-111 and TZ-1113 products with a view to establish partnerships with larger pharmaceutical companies for the clinical co-development of both products;
– in a second phase, planned for 2019, to find a buyer for both products, after the completion of the clinical phase IIa.

TechnoPhage intends to begin the process of internationalization of these two products in a global scale, focusing on the geographical areas in which these two neurological diseases are most prevalent and incident: USA, Europe, and Asia.